C4 Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:CCCC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 319.52 M296.53 M265.49 M359.07 M328.86 M359.4 M Total liabilities 124.38 M122.46 M111.08 M102.49 M94.61 M112.14 M Total equity 195.14 M174.06 M154.41 M256.59 M234.25 M247.26 M Total liabilities & shareholders' equities 319.52 M296.53 M265.49 M359.07 M328.86 M359.4 M Total debt —————— Net debt ——————

News

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (NASDAQ:CCCC) 2026-06-20

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential (NASDAQ:GLUE)

C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout (NASDAQ:CCCC)

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?

Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates